What is AVANIR Pharmaceuticals Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AVANIR Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2014 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AVANIR Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2014.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for AVANIR Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
FRA:AV2B'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5 Med: 21.59 Max: No Debt
Current: No Debt
During the past 13 years, AVANIR Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.50. And the median was 21.59.
AVANIR Pharmaceuticals Cash-to-Debt Historical Data
The historical data trend for AVANIR Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
AVANIR Pharmaceuticals Cash-to-Debt Chart
|
AVANIR Pharmaceuticals Annual Data
|
|
Trend |
Sep05 |
Sep06 |
Sep07 |
Sep08 |
Sep09 |
Sep10 |
Sep11 |
Sep12 |
Sep13 |
Sep14 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
No Debt |
No Debt |
2.43 |
1.88 |
No Debt |
|
AVANIR Pharmaceuticals Quarterly Data
|
|
Dec09 |
Mar10 |
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
Jun14 |
Sep14 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.88 |
1.49 |
2.01 |
3.52 |
No Debt |
Competitive Comparison of AVANIR Pharmaceuticals's Cash-to-Debt
For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVANIR Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where AVANIR Pharmaceuticals's Cash-to-Debt falls into.
AVANIR Pharmaceuticals Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
AVANIR Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Sep. 2014 is calculated as:
AVANIR Pharmaceuticals had no debt (1).
AVANIR Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2014 is calculated as:
AVANIR Pharmaceuticals had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVANIR Pharmaceuticals (FRA:AV2B) Business Description
Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
AVANIR Pharmaceuticals (FRA:AV2B) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AV2B has been successfully added to your